FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209562018> ?p ?o ?g. }

• W3209562018 endingPage "1454" @default.
• W3209562018 startingPage "1454" @default.
• W3209562018 abstract "<h3>Importance</h3> It is uncertain whether anticoagulation is superior to aspirin at reducing recurrent stroke in patients with recent embolic strokes of undetermined source (ESUS) and left ventricular (LV) dysfunction. <h3>Objective</h3> To determine whether anticoagulation is superior to aspirin in reducing recurrent stroke in patients with ESUS and LV dysfunction. <h3>Design, Setting, and Participants</h3> Post hoc exploratory analysis of data from the New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial vs Aspirin to Prevent Embolism in ESUS (NAVIGATE ESUS) trial, a randomized, phase 3 clinical trial with enrollment from December 2014 to September 2017. The study setting included 459 stroke recruitment centers in 31 countries. Patients 50 years or older who had neuroimaging-confirmed ESUS between 7 days and 6 months before screening were eligible. Of the 7213 NAVIGATE ESUS participants, 7107 (98.5%) had a documented assessment of LV function at study entry and were included in the present analysis. Data were analyzed in January 2021. <h3>Interventions</h3> Participants were randomized to receive either 15 mg of rivaroxaban or 100 mg of aspirin once daily. <h3>Main Outcomes and Measures</h3> The study examined whether rivaroxaban was superior to aspirin at reducing the risk of (1) the trial primary outcome of recurrent stroke or systemic embolism and (2) the trial secondary outcome of recurrent stroke, systemic embolism, myocardial infarction, or cardiovascular mortality during a median follow-up of 10.4 months. LV dysfunction was identified locally through echocardiography and defined as moderate to severe global impairment in LV contractility and/or a regional wall motion abnormality. A Cox proportional hazards model was used to assess for treatment interaction and to estimate the hazard ratios for those randomized to rivaroxaban vs aspirin by LV dysfunction status. <h3>Results</h3> LV dysfunction was present in 502 participants (7.1%). Of participants with LV dysfunction, the mean (SD) age was 67 (10) years, and 130 (26%) were women. Among participants with LV dysfunction, annualized primary event rates were 2.4% (95% CI, 1.1-5.4) in those assigned to rivaroxaban vs 6.5% (95% CI, 4.0-11.0) in those assigned aspirin. Among the 6605 participants without LV dysfunction, rates were similar between those assigned to rivaroxaban (5.3%; 95% CI, 4.5-6.2) vs aspirin (4.5%; 95% CI, 3.8-5.3). Participants with LV dysfunction assigned to rivaroxaban vs aspirin had a lower risk of the primary outcome (hazard ratio, 0.36; 95% CI, 0.14-0.93), unlike those without LV dysfunction (hazard ratio, 1.16; 95% CI, 0.93-1.46) (<i>P</i>for treatment interaction = .03). Results were similar for the secondary outcome. <h3>Conclusions and Relevance</h3> In this post hoc exploratory analysis, rivaroxaban was superior to aspirin in reducing the risk of recurrent stroke or systemic embolism among NAVIGATE ESUS participants with LV dysfunction. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT02313909" @default.
• W3209562018 created "2021-11-08" @default.
• W3209562018 creator A5009170752 @default.
• W3209562018 creator A5013436232 @default.
• W3209562018 creator A5039597123 @default.
• W3209562018 creator A5054660298 @default.
• W3209562018 creator A5056529805 @default.
• W3209562018 creator A5064975333 @default.
• W3209562018 creator A5067450403 @default.
• W3209562018 creator A5088620592 @default.
• W3209562018 date "2021-12-01" @default.
• W3209562018 modified "2023-10-10" @default.
• W3209562018 title "Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin" @default.
• W3209562018 cites W2006835595 @default.
• W3209562018 cites W2063528788 @default.
• W3209562018 cites W2102355502 @default.
• W3209562018 cites W2116427214 @default.
• W3209562018 cites W2138595885 @default.
• W3209562018 cites W2141610267 @default.
• W3209562018 cites W2167918232 @default.
• W3209562018 cites W2475974359 @default.
• W3209562018 cites W2576315008 @default.
• W3209562018 cites W2591708623 @default.
• W3209562018 cites W2749026956 @default.
• W3209562018 cites W2769804891 @default.
• W3209562018 cites W2803966697 @default.
• W3209562018 cites W2937018171 @default.
• W3209562018 cites W2938717438 @default.
• W3209562018 cites W2939565435 @default.
• W3209562018 cites W2944467350 @default.
• W3209562018 cites W2945825099 @default.
• W3209562018 cites W3017230206 @default.
• W3209562018 cites W3081141202 @default.
• W3209562018 cites W3164908038 @default.
• W3209562018 cites W4232034913 @default.
• W3209562018 doi "https://doi.org/10.1001/jamaneurol.2021.3828" @default.
• W3209562018 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8546621" @default.
• W3209562018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34694346" @default.
• W3209562018 hasPublicationYear "2021" @default.
• W3209562018 type Work @default.
• W3209562018 sameAs 3209562018 @default.
• W3209562018 citedByCount "19" @default.
• W3209562018 countsByYear W32095620182022 @default.
• W3209562018 countsByYear W32095620182023 @default.
• W3209562018 crossrefType "journal-article" @default.
• W3209562018 hasAuthorship W3209562018A5009170752 @default.
• W3209562018 hasAuthorship W3209562018A5013436232 @default.
• W3209562018 hasAuthorship W3209562018A5039597123 @default.
• W3209562018 hasAuthorship W3209562018A5054660298 @default.
• W3209562018 hasAuthorship W3209562018A5056529805 @default.
• W3209562018 hasAuthorship W3209562018A5064975333 @default.
• W3209562018 hasAuthorship W3209562018A5067450403 @default.
• W3209562018 hasAuthorship W3209562018A5088620592 @default.
• W3209562018 hasBestOaLocation W32095620182 @default.
• W3209562018 hasConcept C126322002 @default.
• W3209562018 hasConcept C127413603 @default.
• W3209562018 hasConcept C164705383 @default.
• W3209562018 hasConcept C168563851 @default.
• W3209562018 hasConcept C2776301958 @default.
• W3209562018 hasConcept C2777185221 @default.
• W3209562018 hasConcept C2777628954 @default.
• W3209562018 hasConcept C2778661090 @default.
• W3209562018 hasConcept C2779161974 @default.
• W3209562018 hasConcept C2780645631 @default.
• W3209562018 hasConcept C500558357 @default.
• W3209562018 hasConcept C71924100 @default.
• W3209562018 hasConcept C78519656 @default.
• W3209562018 hasConceptScore W3209562018C126322002 @default.
• W3209562018 hasConceptScore W3209562018C127413603 @default.
• W3209562018 hasConceptScore W3209562018C164705383 @default.
• W3209562018 hasConceptScore W3209562018C168563851 @default.
• W3209562018 hasConceptScore W3209562018C2776301958 @default.
• W3209562018 hasConceptScore W3209562018C2777185221 @default.
• W3209562018 hasConceptScore W3209562018C2777628954 @default.
• W3209562018 hasConceptScore W3209562018C2778661090 @default.
• W3209562018 hasConceptScore W3209562018C2779161974 @default.
• W3209562018 hasConceptScore W3209562018C2780645631 @default.
• W3209562018 hasConceptScore W3209562018C500558357 @default.
• W3209562018 hasConceptScore W3209562018C71924100 @default.
• W3209562018 hasConceptScore W3209562018C78519656 @default.
• W3209562018 hasIssue "12" @default.
• W3209562018 hasLocation W32095620181 @default.
• W3209562018 hasLocation W32095620182 @default.
• W3209562018 hasLocation W32095620183 @default.
• W3209562018 hasOpenAccess W3209562018 @default.
• W3209562018 hasPrimaryLocation W32095620181 @default.
• W3209562018 hasRelatedWork W2006773714 @default.
• W3209562018 hasRelatedWork W2013904527 @default.
• W3209562018 hasRelatedWork W2014582235 @default.
• W3209562018 hasRelatedWork W2049934312 @default.
• W3209562018 hasRelatedWork W2050341869 @default.
• W3209562018 hasRelatedWork W2095792092 @default.
• W3209562018 hasRelatedWork W2168788799 @default.
• W3209562018 hasRelatedWork W2225807237 @default.
• W3209562018 hasRelatedWork W2397154677 @default.
• W3209562018 hasRelatedWork W4296801435 @default.
• W3209562018 hasVolume "78" @default.
• W3209562018 isParatext "false" @default.

• next